Teva secures stay pending appeal of Orange Book delisting order in US patent dispute with Amneal
A June order requiring Teva Pharmaceuticals USA to delist or correct five “ProAir” HFA inhaler patents in the US Food and Drug Administration’s Orange Book of approved drugs has been put...To view the full article, register now.
Already a subscriber? Click here to view full article